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Tricuspid Valve Surgery
Moving To Europe?*Patrick M. McCarthy, MDT he tricuspid valve has sometimes beenreferred to as the “forgotten valve” becausethere are far more publications about mitral
valve surgery than about tricuspid valve surgery.
In this issue of the Journal, Chikwe et al. (1), from
Mt. Sinai Medical Center in New York, provide an
example of a new focus on the importance of add-
ing tricuspid valve surgery to create a more compre-
hensive approach to patients needing mitral valve
operations. Europe has been ahead of the United
States in this regard for years, and, historically, Eu-
ropean surgeons were more likely to perform
tricuspid valve surgery concomitantly with mitralSEE PAGE 1931valve surgery. Indications for tricuspid valve surgery,
according to guidelines from the European Society of
Cardiology and the European Association for Cardio-
Thoracic Surgery (2), suggested a much more aggres-
sive approach to tricuspid valve surgery than the
U.S. guidelines (3,4). However, guidelines in the
United States have evolved (5), and they now are
similar to the European document. The approach
described by Chikwe et al. reﬂects this change.
It is an easy decision to add tricuspid surgery
for patients undergoing left-sided valve operations
when there is severe tricuspid regurgitation (TR),
especially if these patients have symptoms related to
the tricuspid valve (Class I or Class IIa indications in*Editorials published in the Journal of the American College of Cardiology
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Lifesciences.all guidelines) (1–4). Chikwe et al. (1) suggest early
repair of moderate TR or even when there is only
mild TR in the presence of signiﬁcant annular dila-
tion (>40 mm); this approach results in a higher
freedom from moderate TR at late follow-up
compared with patients who had isolated mitral
valve repair. Additional ﬁndings in these patients
are improved recovery of right ventricular function
and a reduction in pulmonary hypertension (1).
Higher freedom from recurrent TR in treated pa-
tients has been described in other papers, as has
improved late right ventricular function (6,7). A
prospective randomized trial of patients with mod-
erate TR, or less severe TR with a dilated annulus,
showed that even with a relatively small group of
patients (22 in each group), not only was freedom
from recurrent moderate to severe TR better (0% vs.
28% in the untreated group; p ¼ 0.02), but also
clinical improvement was greater (8). The 6-min
walk test improved from baseline in both groups, but
the improvement was greater in the treatment group
compared with the group treated with mitral valve
surgery only (p ¼ 0.008). Therefore, the myth that
TR will resolve after mitral valve surgery has been
disproven by many recent studies and belongs only
in the history books.
We have to weigh the risks against the beneﬁts
of adding tricuspid valve surgery to mitral valve
surgery. In the study by Chikwe et al. (1), there
were no apparent added risks and no increase in
permanent pacemaker use, and studies from the
Society of Thoracic Surgery database indicate that
the risks are now lower if tricuspid valve surgery
is added to mitral valve surgery (9). Quantifying
beneﬁt is more difﬁcult because patients show
clinical beneﬁt related to the mitral valve compo-
nent of the surgical procedure. This study by
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1940Chikwe et al. (1) now adds to the growing litera-
ture demonstrating a beneﬁt from the tricuspid
valve surgery (6–8).
Unfortunately, the Society of Thoracic Surgery
database, using guideline criteria, indicates that we
fall far short of the number of tricuspid valve op-
erations that should be employed, but at Mt. Sinai,
65% of patients undergoing mitral valve operations
also had tricuspid valve surgery. Through deepereducational efforts and dissemination of data, we
should expect to see this approach more widely
adopted.
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